4-(1-methyl-1H-tetrazol-5-yl)benzoic acid | 501662-54-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-(1-methyl-1H-tetrazol-5-yl)benzoic acid
• 英文别名: 4-(1-methyl-1H-Tetrazol-5-YL)-Benzoic acid；4-(1-methyltetrazol-5-yl)benzoic acid
• CAS: 501662-54-0
• 化学式: C₉H₈N₄O₂
• mdl: MFCD09035884
• 分子量: 204.188
• InChiKey: MCMCXXODMGTCCM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.111
• 拓扑面积：
  80.9
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  1-(4-(5-chloro-2-(1H-tetrazol-1-yl)phenyl)-1H-1,2,3-triazol-1-yl)-3-phenylpropane-2-amine hydrochloride 、 4-(1-methyl-1H-tetrazol-5-yl)benzoic acid 在 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 以75%的产率得到N-(1-(4-(5-chloro-2-(1H-tetrazol-1-yl)phenyl)-1H-1,2,3-triazol-1-yl)-3-phenylpropane-2-yl)-4-(1-methyl-1H-tetrazol-5-yl)benzamide
  参考文献：
  名称：

  인자 ＸＩａ 억제 활성을 가지는 신규한 화합물

  摘要：

  This is the translation of the text you provided: This invention relates to a novel compound represented by the chemical formula 1 having pharmacologically effective amounts inhibiting the activity of Factor XIa (Factor XIa, FXIa), its preparation method, and pharmaceutical compositions for the prevention of blood coagulation and the treatment of various thrombotic disorders, comprising the compound as an active ingredient. In the chemical formula 1, A, L, X, Y, Z, and n are as defined in this specification.

  公开号：

  KR20150136294A

文献信息

• [EN] AMINOMETHYL QUINOLONE COMPOUNDS<br/>[FR] COMPOSÉS D'AMINOMÉTHYL-QUINOLONE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2013007676A1

  公开（公告）日：2013-01-17

  The invention relates to JNK inhibitors and corresponding methods, formulations, and compositions for inhibiting JNK and treating JNK-mediated disorders. The application discloses JNK inhibitors, as described below in Formula (I): wherein the variables are as defined herein. The compounds and compositions disclosed herein are useful to modulate the activity of JNK and treat diseases associated with JNK activity. Disclosed are methods and formulations for inhibiting JNK and treating JNK-mediated disorders, and the like, with the compounds, and processes for making said compounds, and corresponding compositions, disclosed herein.

  这项发明涉及JNK抑制剂及相应的用于抑制JNK和治疗JNK介导的疾病的方法、配方和组合物。该申请披露了JNK抑制剂，如下所述的化学式(I)：其中变量如本文所定义。本文披露的化合物和组合物可用于调节JNK的活性并治疗与JNK活性相关的疾病。还披露了用于抑制JNK和治疗JNK介导的疾病等的方法和配方，以及用于制备上述化合物和相应组合物的过程。
• AMINOMETHYL QUINOLONE COMPOUNDS
  申请人：Bilotta Joseph A.

  公开号：US20130018043A1

  公开（公告）日：2013-01-17

  The invention relates to JNK inhibitors and corresponding methods, formulations, and compositions for inhibiting JNK and treating JNK-mediated disorders. The application discloses JNK inhibitors, as described below in Formula I: wherein the variables are as defined herein. The compounds and compositions disclosed herein are useful to modulate the activity of JNK and treat diseases associated with JNK activity. Disclosed are methods and formulations for inhibiting JNK and treating JNK-mediated disorders, and the like, with the compounds, and processes for making said compounds, and corresponding compositions, disclosed herein.

  本发明涉及JNK抑制剂及其相应的方法、配方和组合物，用于抑制JNK并治疗JNK介导的疾病。本申请公开了JNK抑制剂，如下式I所述：其中变量如本文所定义。本文所披露的化合物和组合物，有利于调节JNK的活性并治疗与JNK活性相关的疾病。本文披露了用所述化合物抑制JNK和治疗JNK介导的疾病的方法和配方，以及制备上述化合物和相应组合物的过程。
• US8501732B2
  申请人：——

  公开号：US8501732B2

  公开（公告）日：2013-08-06